SEOUL, Oct. 26 (Korea Bizwire) — The first batch of 2.43 million doses of Moderna vaccines manufactured by South Korean biopharmaceutical firm Samsung Biologics Co. will be provided here this week, health authorities said Tuesday. In May, the biotech unit of Samsung Group signed a contract with the U.S. drugmaker to provide contract manufacturing organization [...]
SEOUL, May 23 (Korea Bizwire) – South Korea, touted as one of most successful countries in containing the new coronavirus pandemic without lockdowns, is gearing up for its next step to emerge as a global vaccine hub, with four COVID-19 vaccines already being or set to be produced here. The country’s vision to become a [...]
WASHINGTON/SEOUL, May 22 (Korea Bizwire) — Samsung Biologics, a South Korean biopharmaceutical firm, signed a deal Saturday to manufacture Moderna’s COVID-19 vaccine at its local factory. Under the agreement, the biotech unit of Samsung Group will provide the U.S. drugmaker with contract manufacturing organization (CMO) services for its mRNA vaccine. It means that some of [...]
SEOUL, April 28 (Korea Bizwire) — Samsung Biologics, a biopharmaceutical unit of South Korea’s top conglomerate Samsung Group, said Tuesday its net income skyrocketed 66.4 percent on-year in the first quarter on the back of increased sales. The company’s net profit reached 61 billion won (US$54.8 million) during the Jan.-April period, compared with a net [...]
SONGDO, March 19 (Korea Bizwire) — South Korean pharmaceutical firm Samsung Biologics Co. will accelerate its new drug development to secure future growth engines, its chief said Friday. Samsung Biologics is a leading contract development and manufacturing organization (CDMO) specializing in the development and manufacturing of biopharmaceutical products for major pharmaceutical firms from both home [...]
SEOUL, Jan. 26 (Korea Bizwire) — Samsung BioLogics, a biopharmaceutical unit of South Korea’s top conglomerate Samsung Group, said Tuesday its net income increased 18.8 percent on-year in 2020 on the back of improved factory utilization and increased sales. The company’s net profit reached 241 billion won (US$217.8 million) in 2020, compared with a net [...]
SEOUL, Nov. 17 (Korea Bizwire) — South Korean pharmaceutical firm Samsung Biologics Co. said Tuesday it has signed a long-term agreement with U.S. pharmaceutical firm Eli Lilly and Company to manufacture a novel coronavirus-neutralizing antibody. Under the contract manufacturing organization (CMO) agreement, Samsung Biologics will provide Eli Lilly’s investigational neutralizing antibody for the treatment of [...]
SEOUL, Sept. 22 (Korea Bizwire) — South Korea’s top pharmaceutical firm, Samsung Biologics Co., said Tuesday it has signed a long-term supply agreement, valued at approximately US$330.8 million, with British-Swedish bio giant AstraZeneca Plc. Under the contract manufacturing organization (CMO) agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its third plant [...]
SEOUL, Aug. 11 (Korea Bizwire) — Samsung Biologics, a biopharmaceutical unit of South Korea’s largest conglomerate Samsung Group, said Tuesday that it will build a fourth plant in the country in response to rising manufacturing demand. The 1.7 trillion-won (US$1.4 billion) plant in Songdo, western Incheon, will have a bioreactor capacity of 256,000 liters, the [...]
SEOUL, July 21 (Korea Bizwire) — Samsung Biologics, a biopharmaceutical unit of South Korea’s largest conglomerate Samsung Group, said Tuesday that it shifted to the black in the second quarter from a year earlier, as costs decreased on the back of an improvement in factory utilization and increased sales. The company posted a net profit [...]